-
Recent Posts
Recent Comments
Patrick J. Halloran,… on Shire Development, LLC et al.… Kevin E Noonan on Shire Development, LLC et al.… Qualities of a Good… on Edwards Life Sciences AG et al… Archives
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- Conception and Reduction to Practice
- Contributory Infringement
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Expert Testimony
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Means-plus-function
- Method claims
- Negative Limitations
- Obviousness
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Prosecution History Estoppel
- Public Use
- Reexamination
- Reissue
- Royalties
- Software
- Summary Judgment
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unjust enrichment
- Willfullness
- Written description
Meta
- America Invents Act Anticipation (35 USC 102) Appeal Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Collateral estoppel Damages Doctrine of equivalents Expert Testimony Generics / ANDA Indefiniteness Inducement to Infringe Inequitable Conduct Infringement Injunction Inter Parties Review (IPR) Inventorship IPR Means-plus-function Obviousness Patentability Preamble Prosecution History Estoppel Reexamination Trademarks Uncategorized Willfullness Written description
Category Archives: Indefiniteness
Tinnus Enterprises, LLC et al. v. Telebrands Corp. et al.
Docket No. 2016-1410 MOORE, WALLACH, STOLL January 24, 2017 Brief Summary: DC grant of PI and no invalidity for indefiniteness or obviousness affirmed. Summary: Telebrands appealed DC entry of preliminary injunction (PI) barring it from selling its “Balloon Bonanza, or … Continue reading
Sonix Technology Co., Ltd. v. Publications International, Ltd. et al.
Docket No. 2016-1449 LOURIE, O’MALLEY, TARANTO January 5, 2017 Brief Summary: DC decision that “visually negligible” is indefinite reversed as the meaning of the term is not “purely subjective” in view of the specification and prosecution history. Summary: Sonix appealed … Continue reading
Posted in Indefiniteness
Leave a comment
Eli Lilly and Company v. Teva Parenteral Medicines, Inc. et al.
Docket No. 2015-2067 REYNA, HUGHES, STOLL January 12, 2017 Brief Summary: DC decision finding of direct infringement by physicians and induced infringement (§ 271(b)) by Teva as well as no obviousness affirmed. Summary: Teva et al. (“Teva”) appealed DC finding … Continue reading
Alfred E. Mann Foundation et al. (“AEM”) v. Cochlear Corporation et al.
Docket No. 2015-1580, -1606, -1607 NEWMAN, CHEN, HUGHES November 17, 2016 Brief Summary: DC decision of indefiniteness of certain claims for failure to disclosure an algorithm affirmed; another found supported by “adequate defining structure”. Finding of no willfulness vacated and … Continue reading
Posted in Indefiniteness, Means-plus-function, Software, Willfullness
Leave a comment
GE Lighting Solutions, LLC v. Lights of America, Inc. et al.
Docket No. 2015-197-82, 2015-2044 PROST, WALLACH, HUGHES October 27, 2016 Non-precedential Brief Summary: DC decision that “elongated” is indefinite affirmed (“an ordinarily skilled artisan cannot, without additional information, differentiate an ‘elongated’ core from a ‘non-elongated’ core”) but indefiniteness decision regarding … Continue reading
Posted in Indefiniteness
Leave a comment
MIT, et al. v. Shire Pharmaceuticals, Inc. et al.
Docket No. 2015-1881 O’MALLEY, CHEN, STOLL October 13, 2016 Brief Summary: DC decision of infringement and no invalidity based on finding of no prosecution history estoppel or indefiniteness affirmed. Summary: MIT appealed DC claim construction after the parties stipulated to … Continue reading
Advanced Ground Information Systems, Inc. v. Life360, Inc.
Docket No. 2015-1732 MOORE, MAYER, WALLACH July 28, 2016 Brief Summary: DC finding that “symbol generator” invoked 112/6 and was indefinite affirmed (computer-implemented functions require disclosure of an algorithm). Summary: AGIS appealed DC decision that certain claims of US 7,031,728 … Continue reading
Posted in Indefiniteness, Means-plus-function
Leave a comment
